Edition:
United Kingdom

China NT Pharma Group Co Ltd (1011.HK)

1011.HK on Hong Kong Stock

2.07HKD
23 May 2018
Change (% chg)

HK$-0.08 (-3.72%)
Prev Close
HK$2.15
Open
HK$2.16
Day's High
HK$2.17
Day's Low
HK$2.06
Volume
6,313,000
Avg. Vol
4,464,020
52-wk High
HK$2.48
52-wk Low
HK$1.61

Latest Key Developments (Source: Significant Developments)

Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo
Wednesday, 18 Apr 2018 

April 18 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®.PFENEX INC - PFENEX RECEIVED A PAYMENT OF $2.5 MILLION UPON SIGNING OF AGREEMENT.PFENEX INC - PFENEX MAY BE ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS OF UP TO $22.5 MILLION BASED ON ACHIEVEMENT OF DEVELOPMENT, SALES-RELATED MILESTONES.PFENEX INC - PFENEX MAY ALSO BE ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON NET PRODUCT SALES.  Full Article

China Nt Pharma Group Co ‍Fy Net Profit Attributable RMB 165.2 Mln VS RMB 116.2 Mln​
Monday, 26 Mar 2018 

March 27 (Reuters) - China Nt Pharma Group Co Ltd <1011.HK>::‍FY REVENUE RMB604.8 MILLION VERSUS RMB359.6 MILLION.‍FY NET PROFIT ATTRIBUTABLE RMB165.2 MILLION VERSUS RMB116.2 MILLION​.‍FINAL DIVIDEND OF HK3.5 CENTS PER SHARE​.  Full Article

BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

* PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®